The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(R)-N-(6-(3((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)pyridin-3-yl)acrylamide ID: ALA4866757
PubChem CID: 164620575
Max Phase: Preclinical
Molecular Formula: C26H26ClN7O
Molecular Weight: 488.00
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: C/C=C/C(=O)Nc1ccc(N2CCC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)nc1
Standard InChI: InChI=1S/C26H26ClN7O/c1-2-6-24(35)31-17-10-11-23(29-13-17)34-12-5-7-18(16-34)32-26-30-15-21(27)25(33-26)20-14-28-22-9-4-3-8-19(20)22/h2-4,6,8-11,13-15,18,28H,5,7,12,16H2,1H3,(H,31,35)(H,30,32,33)/b6-2+/t18-/m1/s1
Standard InChI Key: KXUXIJQYOMQECK-OBNPVOHOSA-N
Molfile:
RDKit 2D
35 39 0 0 0 0 0 0 0 0999 V2000
34.7693 -22.1692 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.7681 -22.9967 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.4830 -23.4096 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
36.1995 -22.9962 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.1967 -22.1656 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
35.4812 -21.7564 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.9148 -23.4077 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
37.6287 -22.9940 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.3382 -23.4088 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.0500 -22.9986 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
39.0529 -22.1731 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.3379 -21.7596 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.6199 -22.1714 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.7636 -23.4127 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.0560 -23.4120 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.1619 -24.4035 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
33.9690 -24.2325 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.7499 -23.6885 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.3006 -23.0796 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.0482 -22.3003 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2456 -22.1287 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.6958 -22.7427 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.9510 -23.5196 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.0547 -21.7568 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
39.7584 -24.2372 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
40.4711 -24.6513 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.1876 -24.2402 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.1868 -23.4109 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.4733 -23.0006 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.9018 -24.6534 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
42.6167 -24.2415 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.3309 -24.6547 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.6175 -23.4164 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
44.0458 -24.2428 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
44.7600 -24.6559 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
4 7 1 0
8 7 1 6
8 9 1 0
8 13 1 0
9 10 1 0
10 11 1 0
11 12 1 0
12 13 1 0
10 14 1 0
15 19 1 0
18 16 1 0
16 17 1 0
17 15 2 0
2 15 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 22 1 0
22 23 2 0
23 18 1 0
1 24 1 0
14 25 2 0
25 26 1 0
26 27 2 0
27 28 1 0
28 29 2 0
29 14 1 0
27 30 1 0
30 31 1 0
31 32 1 0
31 33 2 0
32 34 2 0
34 35 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 488.00Molecular Weight (Monoisotopic): 487.1887AlogP: 5.27#Rotatable Bonds: 6Polar Surface Area: 98.83Molecular Species: NEUTRALHBA: 6HBD: 3#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 5.49CX LogP: 5.07CX LogD: 5.06Aromatic Rings: 4Heavy Atoms: 35QED Weighted: 0.32Np Likeness Score: -1.47
References 1. Jiang B, Jiang J, Kaltheuner IH, Iniguez AB, Anand K, Ferguson FM, Ficarro SB, Seong BKA, Greifenberg AK, Dust S, Kwiatkowski NP, Marto JA, Stegmaier K, Zhang T, Geyer M, Gray NS.. (2021) Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma., 221 [PMID:33945934 ] [10.1016/j.ejmech.2021.113481 ]